The effectiveness and value of tirzepatide for type 2 diabetes mellitus

J Manag Care Spec Pharm. 2022 Jun;28(6):680-684. doi: 10.18553/jmcp.2022.28.6.680.

Authors

Dmitriy Nikitin¹, Grace A Lin^{1

2}, Jon D Campbell¹, Ryan N Hansen³, Elizabeth Brouwer³, Yilin Chen³, Serina Herron-Smith¹, Foluso Agboola¹, Steven D Pearson¹

Affiliations

¹ Institute for Clinical and Economic Review, Boston, MA.
² Department of Medicine and Philip R Lee Institute for Health Policy Studies, University of California, San Francisco.
³ CHOICE Institute, Department of Pharmacy, University of Washington, Seattle.

No abstract available

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Gastric Inhibitory Polypeptide
Humans

Substances

Gastric Inhibitory Polypeptide
tirzepatide